Indian J Pharm Close
 

Figure 3: Apoptosis images of K562 and K562/DOX cells determined by double staining of Heochst 33342 and propidium iodide with Arrary Scan VTIHCS600 High-Contents. A-1~A-4: K562 cells treated with 0.15 μM of doxorubicin in the presence or absence of 1.0 μM of 5,5'-dimethoxylariciresinol-4'-O-β-D-glucoside (DMAG) or 1.0 μM of verapamil for 24 h; A-5~A-8: K562 cells treated with 0.15 μM of doxorubicin in the presence or absence of 1.0 μM of DMAG or 1.0 μM of verapamil for 48 h. B-1~B-4: K562/DOX cells treated with 15.0 μM of doxorubicin in the presence of 1.0 μM of DMAG or 1.0 μM of verapamil for 24 h; B-5~B-8: K562/DOX cells treated with 15.0 μM of doxorubicin in the presence or absence of 1.0 μM of DMAG or 1.0 μM of verapamil for 48 h. A-1, A-5, B-1, B-5: negative control; A-2, A-6, B-2, B-6: DOX treatment group; A-3, A-7, B-3, B-7: DOX in combination with DMAG group; A-4, A-8, B-4, B-8: DOX in combination with verapamil group, ×40

Figure 3: Apoptosis images of K562 and K562/DOX cells determined by double staining of Heochst 33342 and propidium iodide with Arrary Scan VTIHCS600 High-Contents. A-1~A-4: K562 cells treated with 0.15 μM of doxorubicin in the presence or absence of 1.0 μM of 5,5'-dimethoxylariciresinol-4'-O-β-D-glucoside (DMAG) or 1.0 μM of verapamil for 24 h; A-5~A-8: K562 cells treated with 0.15 μM of doxorubicin in the presence or absence of 1.0 μM of DMAG or 1.0 μM of verapamil for 48 h. B-1~B-4: K562/DOX cells treated with 15.0 μM of doxorubicin in the presence of 1.0 μM of DMAG or 1.0 μM of verapamil for 24 h; B-5~B-8: K562/DOX cells treated with 15.0 μM of doxorubicin in the presence or absence of 1.0 μM of DMAG or 1.0 μM of verapamil for 48 h. A-1, A-5, B-1, B-5: negative control; A-2, A-6, B-2, B-6: DOX treatment group; A-3, A-7, B-3, B-7: DOX in combination with DMAG group; A-4, A-8, B-4, B-8: DOX in combination with verapamil group, ×40